 |
|
|
|
 |
|
|
| Article 1 to 10 out of 12 concerning Myriad Genetics, Inc.
|
-
Lundbeck acquires European commercialization rights for Flurizan from Myriad, USA
(05/26/2008)
New drug in final phase III development for the treatment of Alzheimer's disease.
H. Lundbeck A/S and Myriad Genetics, Inc. announced that Lundbeck has acquired European commercialization rights to Myriad's FlurizanŽ (tarenflurbil). FlurizanŽ might have the potential to delay disability in patients suffering from Alzheimer's ...
-
Researchers use the Genome Sequencer System to sequence and assemble the Pinot Noir Genome
(01/03/2008)
454 Life Sciences, a part of Roche Applied Science, announced that researchers from the Istituto Agrario San Michele all'Adige and Myriad Genetics have used the company's first generation instrument, the Genome Sequencer 20 System, to sequence and ...
-
$4 Trillion in Cost Savings to U.S. From New Disease-Modifying Alzheimer's Treatments
(05/18/2007)
Myriad Genetics, Inc. reported that a new study has estimated the potential savings to the United States healthcare system, from a disease-modifying Alzheimer's drug, at up to $4.0 trillion. These savings would be for new cases arising between 2010, ...
-
Epigenomics AG Enters into R&D Collaboration with Myriad Genetics Inc. to Discover DNA Methylation Biomarkers
(05/10/2007)
Epigenomics AG has entered into an R&D collaboration with Myriad Genetics, Inc. to identify and analyze DNA methylation biomarkers that may predict patients' response to an undisclosed marketed oncology drug.Under the agreement, Epigenomics will use ...
-
Myriad and Abbott Enter Into Broad Discovery Collaboration
(04/13/2006)
Myriad Genetics, Inc. and Abbott announced that the two companies have entered into a broad drug discovery collaboration to identify novel therapeutic targets. The collaboration will leverage proprietary technology from both organizations to ...
-
Myriad Genetics' Follow-on Study of Flurizan Demonstrates Continued Benefit in Alzheimer's Disease
(03/14/2006)
Flurizan Continues to Slow Decline in Cognition, Behavior and Daily Activities through 21 Months
Myriad Genetics, Inc. announced that data from its Phase 2 follow-on study of Flurizan(TM) in patients with mild Alzheimer's disease suggest that study participants on 800 mg BID of Flurizan continued to demonstrate increasing benefit through month ...
-
Myriad Genetics is Exclusive Licensee of New Mayo Clinic Patent on Amyloid Lowering Drugs
(07/01/2005)
Myriad Genetics, Inc. announced the issuance of Patent No. 6,911,466 entitled, "Ab42 Lowering Agents". Myriad holds exclusive rights to the patent under a licensing agreement with Mayo Clinic. The patent covers methods of using a broad class of ...
-
Myriad Genetics' Lead Drug Candidate Accepting Enrollment for a Phase 3 Clinical Trial
(05/27/2005)
Myriad Genetics' lead drug candidate, FLURIZAN(TM), is currently accepting enrollment for a Phase 3 clinical trial in Alzheimer's disease. This compound is also being studied in a Phase 2b clinical trial for prostate cancer therapy. Myriad has a ...
-
New Colon Cancer Gene Licensed Exclusively to Myriad Genetics
(04/14/2004)
Myriad's Predictive Medicine Sample Flow Continues to Grow
Salt Lake City. Myriad Genetics, Inc. , announced that it has licensed exclusive rights in the United States to detect mutations in an important new colon cancer gene. Myriad believes that the new colon cancer gene, known as Mut Y Homolog (MYH), ...
-
Myriad Genetics and Abbott Laboratories Expand Collaboration
(01/08/2004)
SALT LAKE CITY, Myriad Genetics, Inc., and Abbott Laboratories, Inc. have expanded their strategic alliance to include a broad new pharmacogenetics program, the Company announced today. The research collaboration will focus on identifying genetic ...
|
|
|
|
|
Top